Ausgabe 4/2018
Inhalt (18 Artikel)
Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
Jing Li, Hengxiu Yan
A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)
Yusuke Tanaka, Yutaka Ueda, Satoshi Nakagawa, Shinya Matsuzaki, Eiji Kobayashi, Yasuhiko Shiki, Yukihiro Nishio, Masahiko Takemura, Toshiya Yamamoto, Kenjiro Sawada, Takuji Tomimatsu, Kiyoshi Yoshino, Tadashi Kimura
Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation
Feng Ni, Chang-you Yan, Sheng Zhou, Peng-yu Hui, Yong-hui Du, Liang Zheng, Jin Yu, Xiao-jian Hu, Zhi-gang Zhang
Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer
Weiwei Huang, Jian Liu, Yi Zeng, Fan Wu, Nani Li, Kan Chen, Yi Hong, LiLi Wang, Hongyu Zhen, Lin Lin
Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects
Hong Zhang, Qingmei Li, Xiaoxue Zhu, Cuiyun Li, Xiaojiao Li, Chengjiao Liu, Yue Hu, Guiling Chen, Haijing Wei, Jing Wang, Zhenwei Shen, Yanhua Ding
The risk factors for oxaliplatin-induced peripheral sensory neuropathy and thrombocytopenia in advanced gastric cancer
Kyoko Yamaguchi, Hitoshi Kusaba, Akitaka Makiyama, Kenji Mitsugi, Keita Uchino, Shingo Tamura, Yoshihiro Shibata, Taito Esaki, Mamoru Ito, Kotoe Takayoshi, Kenji Tsuchihashi, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1
Mukul R. Jain, Jogeswar Mohapatra, Debdutta Bandhyopadhyay, Abhijit Chatterjee, Krishnarup Ghoshdastidar, Dinesh Patel, Ankit Patel, Hitesh Bhayani, Brijesh Kumar Srivastava, Sandeep A. Shedage, Pravin Kadam, Rajesh Sundar, Harilal Patel, Poonam Giri, Prakash Patel, Laxmikant Gupta, Nuggehally R. Srinivas, Pankaj R. Patel, Ranjit C. Desai
Expression of vascular endothelial growth factor receptor 2 and clinical response to lenvatinib in patients with anaplastic thyroid cancer
Haruhiko Yamazaki, Tomoyuki Yokose, Hiroyuki Hayashi, Hiroyuki Iwasaki, Sachie Osanai, Nobuyasu Suganuma, Hirotaka Nakayama, Katsuhiko Masudo, Yasushi Rino, Munetaka Masuda
Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial
Wen Zhang, Chunxia Du, Yongkun Sun, Lin Yang, Chengxu Cui, Zhichao Jiang, Chengfeng Wang, Jinwang Wang, Aiping Zhou
Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy
Hitoshi Shibuya, Susumu Hijioka, Yasunari Sakamoto, Tetsuhide Ito, Keijiro Ueda, Izumi Komoto, Noritoshi Kobayashi, Atsushi Kudo, Hiroaki Yasuda, Hayato Miyake, Junichi Arita, Sho Kiritani, Masafumi Ikeda, Hiroshi Imaoka, Makoto Ueno, Satoshi Kobayashi, Mitsuhiro Furuta, Yoshikuni Nagashio, Gou Murohisa, Taku Aoki, Shigemi Matsumoto, Masayo Motoya, Nobuaki Azemoto, Jun Itakura, Shigeru Horiguchi, Tatsuji Yogi, Tetsuro Kawagoe, Youichi Miyaoka, Fumito Imamura, Michio Senju, Hitoshi Arioka, Kazuo Hara, Masayuki Imamura, Takuji Okusaka
Pharmacodynamic modelling of resistance to epidermal growth factor receptor inhibition in brain metastasis mouse models
Emma C. Martin, Leon Aarons, James W. T. Yates
Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand–foot skin reactions in sorafenib-treated patients
Kosuke Saito, Masafumi Ikeda, Yasushi Kojima, Hiroko Hosoi, Yoshiro Saito, Shunsuke Kondo
An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
Noboru Yamamoto, Hirotsugu Kenmotsu, Koichi Goto, Koji Takeda, Terufumi Kato, Masayuki Takeda, Hidehito Horinouchi, Isao Saito, Akiko Sarashina, Tetsuya Tanaka, Nassim Morsli, Kazuhiko Nakagawa
A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer
Richard Greil, Sigrun Greil-Ressler, Lukas Weiss, Charlotte Schönlieb, Teresa Magnes, Bianca Radl, Gordon T. Bolger, Brigitta Vcelar, Peter P. Sordillo
Phase II trial of capecitabine plus oxaliplatin (CAPOX) as perioperative therapy for locally advanced rectal cancer
Junichi Nishimura, Junichi Hasegawa, Takeshi Kato, Shinichi Yoshioka, Shingo Noura, Yoshinori Kagawa, Masayoshi Yasui, Masakazu Ikenaga, Kohei Murata, Taishi Hata, Chu Matsuda, Tsunekazu Mizushima, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients
Kana Akiyama, Tetsuo Kume, Masafumi Fukaya, Ikue Shiki, Terukazu Enami, Raine Tatara, Michihiro Shino, Takashi Ikeda
A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors
Stephen V. Liu, Susan G. Groshen, Karen Kelly, Karen L. Reckamp, Chandra Belani, Timothy W. Synold, Amir Goldkorn, Barbara J. Gitlitz, Mihaela C. Cristea, I-Yeh Gong, Thomas J. Semrad, Yucheng Xu, Tong Xu, Marianna Koczywas, David R. Gandara, Edward M. Newman
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
Markus Moehler, Arno Schad, Annett Maderer, Ajlan Atasoy, Murielle E. Mauer, Carmela Caballero, Thomas Thomaidis, Jestinah M. Mahachie John, Istvan Lang, Eric Van Cutsem, João Freire, Manfred P. Lutz, Arnaud Roth